Response
- PMID: 26149564
- PMCID: PMC5831562
- DOI: 10.1378/chest.15-0837
Response
Comment on
-
Counterpoint: were industry-sponsored roflumilast trials appropriate? No.Chest. 2014 May;145(5):939-42. doi: 10.1378/chest.14-0114. Chest. 2014. PMID: 24798831 Free PMC article. No abstract available.
-
Roflumilast in COPD.Chest. 2015 Jul;148(1):e31. doi: 10.1378/chest.15-0664. Chest. 2015. PMID: 26149563 No abstract available.
References
-
- Suissa S, Rabe KF. Point: were industry-sponsored roflumilast trials appropriate? Yes. Chest. 2014;145(5):937–939. - PubMed
-
- Muñoz-Esquerre M, Diez-Ferrer M, Montón C. Roflumilast added to triple therapy in patients with severe COPD: a real life study. Pulm Pharmacol Ther. 2015;30:16–21. - PubMed
-
- Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857–866. - PubMed
-
- Gupta S. Side-effects of roflumilast. Lancet. 2012;379(9817):710–711. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical